Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.

Huang SA, Lie JD.

P T. 2013 Jul;38(7):407-19. Review. No abstract available.

PMID:
24049429
[PubMed]
Free PMC Article
2.

Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction.

Lowe G, Bahnson R.

Ther Adv Urol. 2009 Dec;1(5):235-42. doi: 10.1177/1756287210362069.

PMID:
21789070
[PubMed]
Free PMC Article
3.

Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.

Pimentel H, Wald M, Niederberger C.

Int J Impot Res. 2008 Mar-Apr;20(2):145-9. Epub 2007 Dec 13. Review.

PMID:
18075506
[PubMed - indexed for MEDLINE]
4.

Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.

Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP.

Eur Urol. 2009 Feb;55(2):334-47. doi: 10.1016/j.eururo.2008.10.028. Epub 2008 Oct 21. Review.

PMID:
18986755
[PubMed - indexed for MEDLINE]
5.

Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.

Lombardi G, Nelli F, Celso M, Mencarini M, Del Popolo G.

J Sex Med. 2012 Apr;9(4):970-85. doi: 10.1111/j.1743-6109.2011.02615.x. Epub 2012 Feb 3. Review.

PMID:
22304626
[PubMed - indexed for MEDLINE]
6.

Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives.

Costa P, Grivel T, Gehchan N.

Patient Prefer Adherence. 2009 Nov 3;3:105-11.

PMID:
19936152
[PubMed]
Free PMC Article
7.

Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.

Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, Qin X, Ren Z, Ding H, Chen Q, Mao C, Tang J.

Eur Urol. 2013 May;63(5):902-12. doi: 10.1016/j.eururo.2013.01.012. Epub 2013 Jan 31. Review.

PMID:
23395275
[PubMed - indexed for MEDLINE]
8.

Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.

Sung HH, Lee SW.

Korean J Urol. 2012 Jun;53(6):377-85. doi: 10.4111/kju.2012.53.6.377. Epub 2012 Jun 19.

PMID:
22741044
[PubMed]
Free PMC Article
9.

Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.

Megas G, Papadopoulos G, Stathouros G, Moschonas D, Gkialas I, Ntoumas K.

BJU Int. 2013 Jul;112(2):E169-76. doi: 10.1111/j.1464-410X.2012.11561.x. Epub 2012 Dec 18.

PMID:
23253640
[PubMed - indexed for MEDLINE]
10.

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

Dorsey P, Keel C, Klavens M, Hellstrom WJ.

Expert Opin Pharmacother. 2010 May;11(7):1109-22. doi: 10.1517/14656561003698131. Review.

PMID:
20402554
[PubMed - indexed for MEDLINE]
11.

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

Corbin JD, Francis SH, Webb DJ.

Urology. 2002 Sep;60(2 Suppl 2):4-11. Review.

PMID:
12414329
[PubMed - indexed for MEDLINE]
12.

Current management of erectile dysfunction after cancer treatment.

Peltier A, van Velthoven R, Roumeguère T.

Curr Opin Oncol. 2009 Jul;21(4):303-9. doi: 10.1097/CCO.0b013e32832b9d76. Review.

PMID:
19509501
[PubMed - indexed for MEDLINE]
14.

Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.

Bi Y, Stoy P, Adam L, He B, Krupinski J, Normandin D, Pongrac R, Seliger L, Watson A, Macor JE.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1577-80.

PMID:
15006407
[PubMed - indexed for MEDLINE]
15.

An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.

Palit V, Eardley I.

Nat Rev Urol. 2010 Nov;7(11):603-9. doi: 10.1038/nrurol.2010.165. Review.

PMID:
21068761
[PubMed - indexed for MEDLINE]
16.

Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.

Hellstrom WJ.

Int J Clin Pract. 2007 Sep;61(9):1547-54. Epub 2007 Jul 26. Review.

PMID:
17655683
[PubMed - indexed for MEDLINE]
Free Article
17.

Treatment Strategy for Non-Responders to PDE5 Inhibitors.

Park NC, Kim TN, Park HJ.

World J Mens Health. 2013 Apr;31(1):31-5. doi: 10.5534/wjmh.2013.31.1.31. Epub 2013 Apr 23.

PMID:
23658863
[PubMed]
Free PMC Article
18.
19.

Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.

Lombardi G, Macchiarella A, Cecconi F, Del Popolo G.

J Sex Med. 2009 May;6(5):1248-58. doi: 10.1111/j.1743-6109.2008.01205.x. Epub 2009 Feb 9. Review.

PMID:
19210710
[PubMed - indexed for MEDLINE]
20.

[Update of PDE5 inhibitors for the treatment of ischemia-reperfusion].

Hu YY, Wu ZG.

Zhonghua Nan Ke Xue. 2011 Sep;17(9):842-6. Review. Chinese.

PMID:
21961251
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk